Community curated by people like you

Anticoagulants stories

Oct 26, 2026

Bayer wins China approval for stroke prevention drug asundexian

China's drug regulator approved Bayer's blood thinner asundexian for stroke prevention, marking the first approval globally for this new class of anticoagulant. The approval followed a priority review and represents a significant boost for Bayer's pharmaceutical pipeline.

Oct 26, 2026·3 sources

00

Top claims

▪Bristol Myers Squibb and Johnson & Johnson are jointly conducting clinical testing on milvexian, an experimental competitor in the Factor XIa inhibitor drug class
▪The approval of Asundexian by China's National Medical Products Administration followed a priority review designation granted in May 2026 as an accelerated process for urgent medical needs
▪Bayer's broader pharmaceutical pipeline includes newer therapies such as the menopause treatment Lynkuet and the heart treatment Beyonttra

Subtopics

Cardiovascular diseases1 Clinical trials1 Drug approval process1 Drug development1 Pharmaceutical Industry1

Related timelines

Congress

Iran War

Trump administration

US midterm elections

AI Data Center Gold Rush